Key result
A 2.0 μg/kg bolus of remifentanil effectively attenuated the increases in mean arterial pressure and heart rate during double-lumen endobronchial intubation without adverse effects.
Why the study?
Does a bolus dose of remifentanil attenuate hemodynamic changes to laryngoscopic double-lumen endobronchial intubation in ASA I or II patients?
RCT (n=80)
Double-blind
Randomized
No
Does a bolus dose of remifentanil attenuate hemodynamic changes to laryngoscopic double-lumen endobronchial intubation in ASA I or II patients?
Absolute Event Rate: 93.1% vs 131.1%
p-value: p=0.0001
A 2.0 μg/kg bolus of remifentanil effectively attenuates the hemodynamic stress response to double-lumen endobronchial intubation without causing significant hypotension or bradycardia.
Supports 2.0 μg/kg remifentanil bolus for hemodynamic stability during double-lumen intubation; extends opioid attenuation evidence to thoracic airway management.
The purpose of the present study was to determine the optimal dose of bolus remifentanil to attenuate hemodynamic changes to laryngoscopic double-lumen endobronchial intubation.
No takes yet. Share an insight, caveat, or question.
Shin et al. (2007) conducted an RCT in Patients requiring double-lumen endobronchial intubation (n=80). Remifentanil vs. Normal saline was evaluated on Mean arterial pressure at postintubation (p=0.0001). A 2.0 μg/kg bolus of remifentanil effectively attenuated the increases in mean arterial pressure and heart rate during double-lumen endobronchial intubation without adverse effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: